Selumetinib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB11689 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | familial generalized lentiginosis | KG + DL |
| 2 | gastrocutaneous syndrome | KG + DL |
| 3 | rhabdoid tumor | KG + DL |
| 4 | acromelanosis | KG + DL |
| 5 | congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome | KG + DL |
| 6 | Moynahan syndrome | KG + DL |
| 7 | leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome | KG + DL |
| 8 | osteopathia striata-pigmentary dermopathy-white forelock syndrome | KG + DL |
| 9 | peripheral nerve schwannoma | KG + DL |
| 10 | trigeminal schwannoma | KG + DL |
| 11 | microcystic/reticular schwannoma | KG + DL |
| 12 | schwannoma of twelfth cranial nerve | KG + DL |
| 13 | sympathetic neurilemmoma | KG + DL |
| 14 | bilateral parasagittal parieto-occipital polymicrogyria | KG + DL |
| 15 | trichomegaly-retina pigmentary degeneration-dwarfism syndrome | KG + DL |
| 16 | axial spondylometaphyseal dysplasia | KG + DL |
| 17 | amyotrophic lateral sclerosis | KG + DL |
| 18 | lower motor neuron syndrome with late-adult onset | KG + DL |
| 19 | lethal arthrogryposis-anterior horn cell disease syndrome | KG + DL |
| 20 | amyotrophic lateral sclerosis, susceptibility to | KG + DL |
| 21 | amyotrohpic lateral sclerosis type 22 | KG + DL |
| 22 | Mills syndrome | KG + DL |
| 23 | autosomal dominant mitochondrial myopathy with exercise intolerance | KG + DL |
| 24 | monomelic amyotrophy | KG + DL |
| 25 | neurocutaneous melanocytosis | KG + DL |
| 26 | neuroectodermal melanolysosomal disease | KG + DL |
| 27 | benign PEComa | KG + DL |
| 28 | uterine corpus perivascular epithelioid cell tumor | KG + DL |
| 29 | lymphangiomyoma | KG + DL |
| 30 | familial rhabdoid tumor | KG + DL |
| 31 | X-linked lymphoproliferative disease due to SH2D1A deficiency | KG + DL |
| 32 | dermatofibrosarcoma protuberans | KG + DL |
| 33 | neuronopathy, distal hereditary motor | KG + DL |
| 34 | neurofibromatosis, type III, mixed central and peripheral | KG + DL |
| 35 | Watson syndrome | KG + DL |
| 36 | lymphangioleiomyomatosis | KG + DL |
| 37 | extrasystoles-short stature-hyperpigmentation-microcephaly syndrome | KG + DL |
| 38 | severe combined immunodeficiency due to LAT deficiency | KG + DL |
| 39 | cellular schwannoma | KG + DL |
| 40 | melanotic neurilemmoma | KG + DL |
| 41 | fibroblastic neoplasm | KG + DL |
| 42 | heart fibrosarcoma | KG + DL |
| 43 | A20 haploinsufficiency | KG + DL |
| 44 | conventional fibrosarcoma | KG + DL |
| 45 | lung PEComa | KG + DL |
| 46 | kidney fibrosarcoma | KG + DL |
| 47 | low grade fibromyxoid sarcoma | KG + DL |
| 48 | immune dysregulation with inflammatory bowel disease | KG + DL |
| 49 | schwannomatosis | KG + DL |
| 50 | proximal myopathy with extrapyramidal signs | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.